• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.57% Nasdaq Up2.12%

    More On MLM.MI



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    MolMed S.p.A. (MLM.MI)

    0.35 Down 0.01(2.18%) 11:35AM EDT
    ProfileGet Profile for:
    MolMed S.p.A.
    Via Olgettina, 58
    Milan, MI 20132
    Italy - Map
    Phone: 39 02 21 27 71
    Fax: 39 02 21 27 73 25
    Website: http://www.molmed.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. The company’s products include Zalmoxis (TK), a cell based therapy product, which is in Phase III clinical trial in acute leukemia that is used for the treatment of hematological malignancies. Its products also comprise NGR-hTNF, a therapeutic agent for solid tumors, which is in Phase II trials in seven types of solid tumors, such as monotherapy in colorectal cancer, hepatocellular carcinoma, and mesothelioma; and in combination with standard chemotherapeutic agents in small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as in Phase III trials in mesothelioma patients. In addition, the company’s preclinical development products include CAR-CD44v6, an immuno-gene therapy project for the treatment of various hematological malignancies and epithelial tumors. Further, it conducts cell and gene therapy projects in collaboration with third parties, such as the cGMP production of clinical-grade viral vectors; and manufacturing of patient-specific genetically engineered cells. The company was founded in 1996 and is headquartered in Milan, Italy.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MolMed S.p.A.

    Key Executives 
    Dr. Claudio Bordignon M.D.,
    Founder, Chairman, Chairman of the Scientific Advisory Board, Chief Exec. Officer and Pres
    Mr. Andrea Quaglino ,
    Director of Admin., Fin. & Control
    Ms. Marina Del Bue B.Sc., M.B.A.,
    Bus. Devel. & IR Director and Gen. Mang. Bus. & Admin.
    Ms. Cynthia Giuliani ,
    Director of HR
    Mr. Gian Paolo Rizzardi M.D.,
    Director of R&D, Gen. Mang. R&D and Operations
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.